A novel long‐acting glucose‐dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aim: Glucose‐dependent insulinotropic peptide ( GIP ) is an incretin hormone that is released from intestinal K cells in response to nutrient ingestion. We aimed to investigate the therapeutic potential of the novel N‐ and C‐terminally modified GIP analogue AC163794 . Methods: AC163794 was synthesized by solid‐phase peptide synthesis. Design involved the substitution of the C‐terminus tail region of the dipeptidyl peptidase IV ( DPP‐IV )‐resistant GIP analogue [ d ‐Ala 2 ] GIP (1–42) with the unique nine amino acid tail region of exenatide. The functional activity and binding of AC163794 to the GIP receptor were evaluated in RIN‐m5F β‐cells. In vitro metabolic stability was tested in human plasma and kidney membrane preparations. Acute insulinotropic effects were investigated in isolated mouse islets and during an intravenous glucose tolerance test in normal and diabetic Zucker fatty diabetic ( ZDF ) rats. The biological actions of AC163794 were comprehensively assessed in normal, ob/ob and high‐fat‐fed streptozotocin ( STZ )‐induced diabetic mice. Acute glucoregulatory effects of AC163794 were tested in diet‐induced obese mice treated subchronically with AC3174 , the exendatide analogue [Leu 14 ] exenatide. Human GIP or [ d ‐Ala 2 ] GIP (1–42) were used for comparison. Results: AC163794 exhibited nanomolar functional GIP receptor potency in vitro similar to GIP and [ d ‐Ala 2 ] GIP (1–42). AC163794 was metabolically more stable in vitro and displayed longer duration of insulinotropic action in vivo versus GIP and [ d ‐Ala 2 ] GIP (1–42). In diabetic mice, AC163794 improved HbA1c through enhanced insulinotropic action, partial restoration of pancreatic insulin content and improved insulin sensitivity with no adverse effects on fat storage and metabolism. AC163794 provided additional baseline glucose‐lowering when injected to mice treated with AC3174 . Conclusions: These studies support the potential use of a novel GIP analogue AC163794 for the treatment of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Elliott, R. M., Morgan, L. M., Tredger, J. A., Deacon, S., Wright, J., & Marks, V. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1380159 · Cited by 695
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Functional GIP Receptors Are Present on Adipocytes
Yip, R. G.-C., Boylan, M. O., Kieffer, T. J., & Wolfe, M. M. (1998) · Endocrinology · doi:10.1210/endo.139.9.6288 · Cited by 237
Lynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208
Piteau, S., Olver, A., Kim, S.-J., Winter, K., Pospisilik, J. A., Lynn, F., Manhart, S., Demuth, H.-U., Speck, M., Pederson, R. A., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.115 · Cited by 130 · cited 1×
“In addition, reduction of hyperglycaemia by phlorizin reversed resistance to GIP in diabetic rats [19].”
BackgroundGault, V. A., Kerr, B. D., Harriott, P., & Flatt, P. R. (2011) · Clinical Science · doi:10.1042/cs20110006 · Cited by 125
Flatt, P. R. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02455.x · Cited by 68 · cited 2×
“There is considerable evidence that GIP plays a role in fat homeostasis, therefore, one potential side effect of GIP-based therapies may be to increase adiposity [12].”
Background
Cited by
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Nørregaard, P. K., Deryabina, M. A., Tofteng Shelton, P., Fog, J. U., Daugaard, J. R., Eriksson, P., Larsen, L. F., & Jessen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13034 · Cited by 116
Metadata
- Authors
- Tatarkiewicz, K., Hargrove, D. M., Jodka, C. M., Gedulin, B. R., Smith, P. A., Hoyt, J. A., Lwin, A., Collins, L., Mamedova, L., Levy, O. E., D'Souza, L., Janssen, S., Srivastava, V., Ghosh, S. S., & Parkes, D. G.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-08-19
- Volume
- 16
- Issue
- 1
- Pages
- 75-85
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2123015247
- Cited by
- 32
- References
- 11
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel long‐acting glucose‐dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents. https://app.cochat.ai/papers/10.1111/dom.12181
- The paper
- Tatarkiewicz, K., Hargrove, D. M., Jodka, C. M., Gedulin, B. R., Smith, P. A., Hoyt, J. A., Lwin, A., Collins, L., Mamedova, L., Levy, O. E., D'Souza, L., Janssen, S., Srivastava, V., Ghosh, S. S., & Parkes, D. G. (2014). A novel long‐acting glucose‐dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12181
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.